Alain Mina
@dralainmina
Head of MDS and Myeloid Malignancies Unit at NIH-NCI Immunodeficiency and Cellular Therapy Branch
Our perspectives @NIH @fredhutch @StanfordMed in @BloodJournal on How I reduce and treat posttransplant relapse of #MDSsm ashpublications.org/blood/article-…
Revisiting #aminmaalouf This ageless piece of art seems particularly relevant nowadays.
Dr. Rami Komrokji is personally inviting YOU to #SOHO2025. Don't let him down. Register today at soho.click/2025. 💯 @Ramikomrokji
FDA Eliminates Risk Evaluation and Mitigation Strategies (REMS) for Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies | FDA fda.gov/vaccines-blood…
Excited to see our NHLBI work on infections and immunodeficiency in patients with #telomere biology disorders now published in @BloodPortfolio. >1/3 had significant infection history and nearly 1/2 t-lymphopenia. @FernandoCatto & @fergutierrezro1. ashpublications.org/blood/article-…
I've long been fascinated by the role of iron chelation- and its disordered metabolism- in MDS, particularly in the context of transplantation. This effort led by @FiekeHoff @StevenPavletic and @DrEdSchulz emerged from that curiosity. doi.org/10.1016/j.blre…
I’m an oncologist. Here are 11 science-based ways to reduce your cancer risk. My latest essay @washingtonpost (and I practice what I preach!) @SylvesterCancer @UMiamiHealth @JCO_ASCO @ASH_hematology washingtonpost.com/wellness/2025/…
Fantastic talk by @Dr_AmerZeidan @YaleCancer at #MDS25 @MDSFoundation, using '#BoulevardofBrokenDreams' to describe the challenges in higher-risk MDS drug development. #The18thInternationalCongress on #MDS youtu.be/Soa3gO7tL-c?si…
Myelodysplastic syndromes/neoplasms are a heterogenous group of clonal stem cell disorders characterized by morphological dysplasia, defective hematopoiesis, and recurrent genetic abnormalities. ow.ly/TA2750VLGNJ #HowITreat #myeloidneoplasia
When someone I look up to so much sends me a pic like this…
"Many brilliant people from my country have lost everything to war. They may be just as capable as me, or even more so, but they have not had the same chances," Dr. Elias Jabbour of @MDAndersonNews wrote in this SOHO Insider letter. sohoinsider.com/leukemia/the-f…
US Geriatric Assessment Practices for Older Adults Undergoing Hematopo... sciencedirect.com/science/articl… In a first of its kind team effort with a so grateful for the commitment and mentorship by all! @MediHumdani,Andy Artz, Paul Carpenter @ASTCT improving our survey methodologies🤞🏼
Bidding farewell to a giant, a mentor, and above all, a friend. Congratulations @StevenPavletic on an incredible career; can’t wait to see what your next chapter holds. @NIH @theNCI
I enjoyed reading/learning about TI-CH paper in @NEJM =>Tumor-Infiltrating Clonal Hematopoiesis | Work from @oriol_pich @Elsa2Bernard @PapaemmanuilLab, @CharlesSwanton + team! Editorial by @DanaFarber Ebert/Weeks nejm.org/doi/full/10.10…
Novel investigational therapies in lower-risk MDS - @madanatyazan @Ramikomrokji oncodaily.com/url/274245 #MDS #Cancer #OncoDaily #Oncology #GlobalAwareness #FightAgainstCancer
6th Annual MDS/MPN US Focus Meeting kicks off! Stellar agenda by co-chairs @Ramikomrokji & @bose_prithviraj , opening remarks #RyanFitzpatrick @_MDEducation. Let the learning begin! #HemOnc #MDS #MPN #MedEd
Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL) | Leukemia nature.com/articles/s4137…
In this episode of ASTCT Talks, @DrCCutler is joined by @StevenPavletic, the GVHD and Late Effects Section and Myeloid Malignancies Program Director at @NIH. Listen at the link here or wherever you get podcasts: ow.ly/x8oJ50VlXMe
Thrilled to see our effort on behalf of @ic_MDS group out in @BloodJournal about reducing clinical trial eligibility barriers for our MDS patients. Commentary by Lionel Ades on ‘ releasing the brake’ on eligibility criteria. @Dr_AmerZeidan #mdssm ashpublications.org/blood/article/…
#MDSs are heterogeneous stem cell malignancies characterized by poor prognosis and no curative therapies outside of allogeneic hematopoietic stem cell transplantation. ow.ly/URvQ50VfXra #clinicaltrialsandobservations #myeloidneoplasia